BPC-157: origin, preclinical research and regulatory status
Prepared by: Research Desk. Sources are linked for verification.
Published 19 October 2026
At a glance
- Type: synthetic pentadecapeptide (15 amino acids)
- Origin: partial sequence of a protein fraction described in human gastric juice
- Research stage: mostly animal and cell studies; very limited human data
- Regulatory status: not approved as a medicine by any major regulator; listed by the World Anti-Doping Agency (WADA)
What BPC-157 is
BPC-157 is a 15-amino-acid peptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. The name stands for "body protection compound", a protein fraction that researchers described in human gastric juice. BPC-157 is a partial sequence of that fraction and is produced synthetically for laboratory work. It is often called a "stable gastric pentadecapeptide" in the literature because it was reported to remain intact in gastric juice for longer than many short peptides.
Research history
Almost all of the early work on BPC-157 came from one research group at the University of Zagreb, led by Predrag Sikiric, starting in the early 1990s. That group has published a very large number of papers, mostly in rats, covering the gastrointestinal tract, blood vessels, tendons, ligaments, muscle and the nervous system. Reviews by the same group, such as Seiwerth et al. (2018) and Sikiric et al. (2025), summarise this body of work.
A feature of the field that matters for anyone reading it is concentration: a large share of the literature comes from a single laboratory, and independent replication by unrelated groups is limited. Recent independent systematic reviews have pointed this out.
Mechanisms studied in preclinical work
Preclinical papers describe several possible mechanisms. None of them has been confirmed in controlled human research.
- Cell migration and survival in culture. In a study of rat tendon explants and tendon fibroblasts, Chang et al. (2011) reported faster outgrowth of cells from explants, more cell migration and spreading, and higher cell survival under oxidative stress, without a direct effect on cell proliferation. The authors linked these findings to activation of the FAK-paxillin signalling pathway.
- Blood vessel formation. Several rat studies describe effects on angiogenesis and on the expression of vascular endothelial growth factor receptor 2 (VEGFR2).
- Nitric oxide system. The Zagreb group has proposed interactions with the nitric oxide (NO) system as a common thread across many of its models.
- Gastrointestinal models. Much of the original work used rodent models of gastric and intestinal lesions, which is where the "gastric pentadecapeptide" label comes from.
Animal and cell results are early-stage biology. Effects seen in rats or in a culture dish often do not carry over to people.
The published research landscape
The gap between the animal literature and the human literature is the defining feature of BPC-157 research.
- A 2025 systematic review in HSS Journal by Vasireddi et al. screened the literature up to June 2024 from an orthopaedic sports medicine perspective. It found that most evidence comes from preclinical models and noted that the compound lacks US Food and Drug Administration (FDA) approval and is banned in professional sport.
- A 2026 systematic review by Poolton et al., registered with PROSPERO and searched up to June 2026, looked only for studies in humans. It found three small studies with 30 participants in total, all judged to be of poor methodological quality. The certainty of evidence was rated very low, and the authors concluded that BPC-157 should only be studied in humans within ethically approved, regulated, high-quality clinical trials.
In short, there are no published large, randomised, placebo-controlled human trials of BPC-157. Claims about effects in people are not supported by the current literature.
Regulatory status
- United States. BPC-157 is not an FDA-approved drug. FDA's page on bulk drug substances that may present significant safety risks lists BPC-157 among substances that were in category 2 before their nominations were withdrawn. FDA notes possible immunogenicity, peptide-related impurities and a lack of safety information for the proposed routes.
- Sport. WADA's Prohibited List names BPC-157 under S0 (non-approved substances), prohibited at all times.
- Elsewhere. We found no marketing authorisation for BPC-157 from the European Medicines Agency or other major regulators as of 19 October 2026.
Limitations of the evidence
- Most studies come from one research group.
- Most studies are in rats; very few are in humans, and those are small and uncontrolled.
- Product identity and purity vary across sources, which affects the reproducibility of laboratory work. Batch-level certificates of analysis are the minimum documentation a laboratory should expect.
Where researchers source it
Purita is a store that lists BPC-157 for laboratory research use only. Its product page carries the label "For Research Use Only. Not for human or animal administration."
Affiliate disclosure: this is a paid link. PeptideDiscoveryAI earns a commission if a purchase is made through it, at no extra cost to the buyer. A listing is not an endorsement or a statement about product quality. See the affiliate disclosure.